We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Synchrotron X-Ray Crystallography Generates Insulin-Insulin Receptor Binding Images

By LabMedica International staff writers
Posted on 24 Jan 2013
Print article
The light generated by a state-of-the-art particle accelerator was used to capture X-ray crystallographic images of the three-dimensional interaction between insulin and its receptor.

Insulin receptor signaling has a central role in mammalian biology, regulating cellular metabolism, growth, division, differentiation, and survival. Insulin resistance contributes to the development of diseases such as type II diabetes mellitus and Alzheimer’s disease. Abnormal signaling generated by cross talk with the homologous type 1 insulin-like growth factor receptor (IGF1R) occurs in various cancers. Despite more than thirty years of research, it has not been possible to document the three-dimensional structure of the insulin-insulin receptor due to the complexity of producing the receptor protein.

In a paper published in the January 9, 2013, online edition of the journal Nature an international research time described the use of the Australian Synchrotron to capture the three-dimensional structure of insulin bound to the insulin receptor.

The Australian Synchrotron (Clayton, Australia) is a light source facility that uses particle accelerators to produce a beam of high-energy electrons that are placed within a storage ring that circulates the electrons to create synchrotron light. The electron beams travel at just under the speed of light - about 299,792 kilometers per second, and the intense light they produce is filtered and adjusted to travel down separate beamlines to separate end stations where are placed a variety of experimental equipment including one for protein crystallography.

X-ray crystallographic images generated by the Synchrotron revealed the sparse direct interaction of insulin with the first leucine-rich-repeat domain (L1) of the insulin receptor. Instead, the hormone engaged the insulin receptor carboxy-terminal alpha-chain (alphaCT) segment, which was itself remodeled on the face of L1 upon insulin binding. Contact between insulin and L1 was restricted to insulin B-chain residues. The alphaCT segment displaced the B-chain C-terminal beta-strand away from the hormone core, revealing the mechanism of a long-proposed conformational switch in insulin upon receptor engagement. This mode of hormone-receptor recognition is thought to be novel within the broader family of receptor tyrosine kinases.

"We have now found that the insulin hormone engages its receptor in a very unusual way," said senior author Dr. Michael C. Lawrence, associate professor of structural biology at Walter and Eliza Hall Institute of Medical Research (Melbourne, Australia). "Both insulin and its receptor undergo rearrangement as they interact - a piece of insulin folds out and key pieces within the receptor move to engage the insulin hormone."

"Understanding how insulin interacts with the insulin receptor is fundamental to the development of novel insulins for the treatment of diabetes," said Dr. Lawrence. "Until now we have not been able to see how these molecules interact with cells. We can now exploit this knowledge to design new insulin medications with improved properties, which is very exciting. Insulin is a key treatment for diabetics, but there are many ways that its properties could potentially be improved. This discovery could conceivably lead to new types of insulin that could be given in ways other than injection, or an insulin that has improved properties or longer activity so that it does not need to be taken as often. It may also have ramifications for diabetes treatment in developing nations, by creating insulin that is more stable and less likely to degrade when not kept cold, an angle being pursued by our collaborators. Our findings are a new platform for developing these kinds of medications."

Related Links:
Australian Synchrotron
Walter and Eliza Hall Institute of Medical Research


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
HPV Molecular Controls
ZeptoMetrix® HPV Type 16, 18, 45 & 68 Molecular Controls
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.